Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Dignam

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Bayesian Analysis|March 18, 2011
Bayesian Hierarchical Multiresolution Hazard Model for the Study of Time-Dependent Failure Patterns in Early Stage Breast CancerVanja Dukić, James Dignam
Methods in Molecular Biology (Clifton, N.J.)|March 14, 2002
Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacyJames Dignam, John Bryant, Soonmyung Paik
Clinical Trials (London, England)|June 14, 2024
Scaling and interpreting treatment effects in clinical trials using restricted mean survival timeTheodore Karrison, Chen Hu, James Dignam
Journal of the American Statistical Association|January 27, 2015
A Multiresolution Hazard Model for Multicenter Survival Studies: Application to Tamoxifen Treatment in Early Stage Breast CancerPeter Bouman, Xiao-Li Meng, James Dignam, et al.
Statistics in Medicine|April 20, 2016
Joint modelling of longitudinal and multi-state processes: application to clinical progressions in prostate cancerLoïc Ferrer, Virginie Rondeau, James Dignam, et al.
Lancet (London, England)|September 8, 2004
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trialsBernard Fisher, Jong-Hyeon Jeong, John Bryant, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2004
Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18Terry H Wu, Christine N Pabin, Zhihai Qin, et al.
Breast Cancer Research and Treatment|October 13, 2007
Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancersMinjie Wei, Jinhua Xu, James Dignam, et al.
Cancer|January 16, 2007
A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablationSupriya G Mohile, Kathryn Bylow, William Dale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2004
Benefits and costs of interventions to improve breast cancer outcomes in African American womenJeanne S Mandelblatt, Clyde B Schechter, K Robin Yabroff, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Bayesian Analysis|March 18, 2011
Bayesian Hierarchical Multiresolution Hazard Model for the Study of Time-Dependent Failure Patterns in Early Stage Breast CancerVanja Dukić, James Dignam
Methods in Molecular Biology (Clifton, N.J.)|March 14, 2002
Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacyJames Dignam, John Bryant, Soonmyung Paik
Clinical Trials (London, England)|June 14, 2024
Scaling and interpreting treatment effects in clinical trials using restricted mean survival timeTheodore Karrison, Chen Hu, James Dignam
Journal of the American Statistical Association|January 27, 2015
A Multiresolution Hazard Model for Multicenter Survival Studies: Application to Tamoxifen Treatment in Early Stage Breast CancerPeter Bouman, Xiao-Li Meng, James Dignam, et al.
Statistics in Medicine|April 20, 2016
Joint modelling of longitudinal and multi-state processes: application to clinical progressions in prostate cancerLoïc Ferrer, Virginie Rondeau, James Dignam, et al.
Lancet (London, England)|September 8, 2004
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trialsBernard Fisher, Jong-Hyeon Jeong, John Bryant, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2004
Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18Terry H Wu, Christine N Pabin, Zhihai Qin, et al.
Breast Cancer Research and Treatment|October 13, 2007
Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancersMinjie Wei, Jinhua Xu, James Dignam, et al.
Cancer|January 16, 2007
A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablationSupriya G Mohile, Kathryn Bylow, William Dale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2004
Benefits and costs of interventions to improve breast cancer outcomes in African American womenJeanne S Mandelblatt, Clyde B Schechter, K Robin Yabroff, et al.
Pageof 3